The well-described role of TXA2 as a potent bronchoconstrictor suggested a novel therapeutic approach for allergic lung disease; however, TXAS inhibitors and TP receptor antagonists have shown little efficacy in the treatment of asthma patients (54). The gene discussed is TBXAS1; the disease is asthma.